Ponesimod - Johnson & Johnson Innovative Medicine
Alternative Names: ACT-128800; Compound 8bo - Actelion; PONVORY; R-3477; RG 3477Latest Information Update: 05 Aug 2024
At a glance
- Originator Actelion Pharmaceuticals
- Developer Actelion Pharmaceuticals; Janssen Pharmaceuticals; Johnson & Johnson Innovative Medicine
- Class Antipsoriatics; Chlorobenzenes; Imines; Phenyl ethers; Small molecules; Thiazolidines
- Mechanism of Action Sphingosine 1 phosphate receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Multiple sclerosis
- No development reported Graft-versus-host disease
- Discontinued Plaque psoriasis
Most Recent Events
- 31 Jul 2024 Vanda Pharmaceuticals announces intention to submit Investigational New Drug (IND) application with the US FDA for Psoriasis
- 31 Jul 2024 Vanda Pharmaceuticals announces intention to submit Investigational New Drug (IND) application with the US FDA for Ulcerative colitis
- 08 May 2024 Vanda Pharmaceuticals plans a phase III trial for Psoriasis in the US by the end of 2024